A highly potent nanobody-based bispecific therapeutic provides broad-spectrum protection against ebolavirus - PubMed
3 hours ago
- #bispecific-antibody
- #nanobody
- #ebolavirus
- Identified two camelid-derived nanobodies (1A10 and BA2) that neutralize EBOV, SUDV, and BDBV in vitro and protect female rodents against these pathogens.
- High-resolution cryo-EM structures revealed that 1A10 and BA2 bind to conserved but non-overlapping epitopes near the GP1 base and GP2's internal fusion loop (IFL).
- Engineered a bispecific antibody (BA2-1A10) via GS linker-mediated IgG-Fc fusion, providing highly potent protection against EBOV, SUDV, and BDBV in female rodents.
- The study demonstrates a structure-guided bispecific nanobody strategy for pan-ebolavirus therapy, highlighting compact antibodies for next-generation antivirals.
- Authors T.C.T., M.H.W., S.C., and E.T.L. are named inventors on patents covering the sequences of the 1A10 and BA2 nanobodies for Ebola virus infection treatment.